Breaks Categories: Stock Spotlights

MondayOct 31, 2022 2:42 pm

BioMedNewsBreaks – Quad M Solutions Inc. (MMMM) Commences Application to Dual List on Upstream

Quad M Solutions (OTC: MMMM), a staffing company providing modern health care solution benefits, today announced that it has begun the application process for dual listing on Upstream, the next-generation trading app for digital securities and NFTs powered by Horizon Fintex (“Horizon”) and MERJ Exchange Limited (“MERJ”). According to the update, the planned dual listing is designed to provide Quad M with the opportunity to access a global, digital-first investor base that can trade using the USDC digital currency along with credit, debit, PayPal, and USD, unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in OTC-listed…

Continue Reading

MondayOct 31, 2022 1:52 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical innovator staking out its own position within the competitive field of research, having already progressed to human trials evaluating its novel glioblastoma multiforme (“GBM”) solution, known as Berubicin (or WP744). “Berubicin is a patented doxorubicin (‘Dox’) analog – an anthracycline chemotherapy agent novel in its ability to cross the blood-brain barrier to target tumors directly. Tested against Dox in cancer cells, Berubicin showed a greater capacity to destroy or damage the cancers. In models evaluating intracranial gliomas, Berubicin showed a greater capacity to prolong life than temozolomide, another standard of care for GBM,”…

Continue Reading

MondayOct 31, 2022 1:12 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Pleased with Safety Profile of Its PRV-002 Concussion Treatment

Odyssey Health (OTC: ODYY) recently announced the completion of the second Cohort of its Phase I Multi-Day Ascending Dosing (“MAD”) clinical trial. “Odyssey’s trial involved administering its novel drug to treat concussions, PRV-002, to healthy human subjects to determine drug safety. A total of 40 healthy subjects took part in the study. In Cohort I, eight patients received a low dose of the drug, and in Cohort II, patients received a high dose of the drug. The second Cohort reflected the success of the first, where the drug was well tolerated and proved safe with no severe adverse events reported,”…

Continue Reading

WednesdayOct 26, 2022 1:35 pm

BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Designed to Expedite Return to Work, Play Following Concussive Episode

Odyssey Health (OTC: ODYY), a medical company with a focus in the area of life-saving medical solutions, has developed a fully synthetic, non-naturally occurring neurosteroid known as PRV-002 intended to treat concussion or mild traumatic brain injury (“mTBI”). “Designed to be administered within a few minutes of a concussive episode, PRV-002 induces an intracellular steroid receptor in brain cells, with the stimulation of this receptor activating multiple gene response elements that promote transcription of anti-inflammatories, antioxidants and efflux channels that remove excess fluid and debris. To put it simply, PRV-002 is intended to reduce swelling, oxidative stress and inflammation, and…

Continue Reading

FridayOct 21, 2022 3:05 pm

BioMedNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) Patented Breakthrough Technology Poised to Disrupt ECG Patch Market

HeartBeam (NASDAQ: BEAT) recently received a patent from the United States Patent and Trademark Office for its 12-lead electrocardiogram (“ECG”) patch monitor for the detection of acute coronary syndrome (“ACS”) and cardiac arrhythmia. “The new patent expands on a previously granted patent for a 12-lead ECG patch monitor technology. HeartBeam noted that the patent opens a pathway to a disruptive ischemia and arrhythmia detection ECG patch product. In addition, the innovation builds on HeartBeam’s growing intellectual property portfolio that could enable 12-lead ECG diagnostics outside of a medical setting… Currently, the ECG patch monitor market is limited to detecting arrhythmias…

Continue Reading

MondayOct 17, 2022 1:36 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Continues Focus to Create the Best Psychedelic Therapies for Patients

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. “The in-human trial is critical to the company’s continued development of CYB003, a deuterated psilocybin analog that Cybin believes has potential to successfully address the challenges and limitations of oral psilocybin. According to the company’s preclinical research, CYB003 achieved less variability in plasma levels, along with faster onset of action, improved brain penetration, and shorter duration…

Continue Reading

MondayOct 17, 2022 1:06 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Anticipating 2023 IND Application for Secondary Portfolio Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is currently conducting a potentially pivotal global phase 2 clinical trial in humans to test the effectiveness of its anti-glioblastoma (“GBM”) drug candidate – Berubicin. Testing of Berubicin resulted in a notable success with evidence of improved survival among a dozen safety trial participants recruited by the drug’s original developer over 15 years ago. In its annual stockholder meeting, the company also provided an update for its secondary drug portfolio WP1244. The anthracycline-based substance, being evaluated for the treatment of brain cancers, ovarian and lymphomas, “has produced a new derivative as WP1874 with…

Continue Reading

MondayOct 17, 2022 12:54 pm

BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Designed to Mitigate Short- and Long-Term Effects of mTBI

Odyssey Health (OTC: ODYY) early last year acquired PRV-002, a drug candidate for concussed patients to mitigate both short-term and long-term consequences of concussion. Concussion or mTBI “is caused by a jolt, blow or force to the head that changes the brain’s function. This change often results in myriad consequences ranging from emotional and somatic changes to cognitive impairment and physical symptoms… In most cases, concussion symptoms resolve within a few days or weeks as the damaged pathways rebuild and strengthen through repetition, use and cleanup of cell debris. However, there has been growing concern that mTBI may be associated…

Continue Reading

FridayOct 14, 2022 12:06 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Executes on Several Clinical, Operational Advancements in Pursuit of GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently released its financial results for the second quarter of the fiscal year ended June 30, 2022. “CNS kicked off Q3 2022 with approximately $9 million in cash, and working capital of approximately $10.3 million, which, it is confident, will fund its operations into the 2023 calendar year. Currently, the company is exploring the full potential of its lead product candidate, Berubicin. Results from clinical studies over the last six months have proven fruitful,…

Continue Reading

MondayOct 03, 2022 12:56 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Poised to Bring ‘Potentially Impactful’ Therapy to GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company specializing in developing novel treatments for brain tumors, has focused on its lead drug candidate, Berubicin, to potentially treat glioblastoma (“GBM”). “CNS has since made significant headway, even receiving FDA Fast Track Designation, which now offers it an accelerated path to approval for Berubicin. ‘With this designation, we now have an accelerated pathway to approval for Berubicin and a clear opportunity to more expediently bring this potentially impactful investigational therapy to individuals battling this challenging disease,’ noted CNS CEO John Climaco. GBM’s median survival from initial diagnosis is less than 15…

Continue Reading